Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Osteosarcoma
The commonest bone cancer in teenagers; relapsed and metastatic disease remain hard to treat.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:14 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
171
Phase 1 to 3, interventional
For relapsed or refractory disease
43%
73 trial titles name relapsed, refractory or recurrent disease
Led by industry
21%
36 trials with a company as lead sponsor
7 of the 171 osteosarcoma trials are Phase 3; 15 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of osteosarcoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 42 of 171 trials name no segment and are listed as Untagged.
Segment:All1L1L · Adjuvant1L · Advanced or metastatic1L · Locally advanced1L · Relapsed or refractory2L+Advanced or metastaticB7-H3B7-H3 · 1LB7-H3 · Relapsed or refractoryGD2 · Relapsed or refractoryLocally advancedMaintenanceRelapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Doxorubicin Hydrochloride National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT05691478, NCT02306161, NCT06820957 |
| Cyclophosphamide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Small molecule | Ph3 | NCT02306161, NCT06820957 |
| Etoposide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161, NCT06820957 |
| Ifosfamide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Small molecule | Ph3 | NCT02306161, NCT06820957 |
| Vincristine Sulfate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161, NCT06820957 |
| Cabozantinib S-malate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT05691478 |
| Doxorubicin National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Doxorubicin National Cancer Institute (NCI) | 1L · Locally advanced | Other or not recognised | Ph2/Ph3 | NCT02180867 |
| Doxorubicin Hydrochloride National Cancer Institute (NCI) | 1L · Locally advanced | Other or not recognised | Ph2/Ph3 | NCT02180867 |
| Etoposide Phosphate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Experimental group : Cabometyx ® Gustave Roussy, Cancer Campus, Grand Paris | Advanced or metastatic | Other or not recognised | Ph3 | NCT07871864 |
| Ganitumab National Cancer Institute (NCI) | 1L · Advanced or metastatic | Antibody | Ph3 | NCT02306161 |
| Gemcitabine combined with docetaxel Hansoh BioMedical R&D Company | 2L+ | Other or not recognised | Ph3 | NCT06935409 |
| HS-20093 Hansoh BioMedical R&D Company | 2L+ | Other or not recognised | Ph3 | NCT06935409 |
| Ifosfamide National Cancer Institute (NCI) | 1L · Locally advanced | Small molecule | Ph2/Ph3 | NCT02180867 |
| Irinotecan Hydrochloride Children's Oncology Group | 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT06820957 |
| Methotrexate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT05691478 |
| Pazopanib National Cancer Institute (NCI) | 1L · Locally advanced | Small molecule | Ph2/Ph3 | NCT02180867 |
| Pazopanib Hydrochloride National Cancer Institute (NCI) | 1L · Locally advanced | Small molecule | Ph2/Ph3 | NCT02180867 |
| Regorafenib Children's Oncology Group | 1L · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT06820957 |
| Vincristine National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Temozolomide Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT06541262, NCT04337177, NCT04901702 +3 |
| Cyclophosphamide M.D. Anderson Cancer Center | Relapsed or refractory | Small molecule | Ph2 | NCT03449108, NCT03709680, NCT07227571, NCT01804634 +1 |
| Cyclophosphamide M.D. Anderson Cancer Center | Advanced or metastatic | Small molecule | Ph1/Ph2 | NCT06474676, NCT07194044, NCT05621668, NCT05703854 |
| Fludarabine M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph2 | NCT03449108, NCT07227571, NCT01804634, NCT01625351 |
| Irinotecan Pfizer | Relapsed or refractory | Other or not recognised | Ph2 | NCT03709680, NCT06541262, NCT03678883, NCT04238819 |
| Doxorubicin Milton S. Hershey Medical Center | Untagged | Other or not recognised | Ph2 | NCT07321912, NCT07477457, NCT02811523 |
| Irinotecan Eli Lilly and Company | Untagged | Other or not recognised | Ph2 | NCT05440786, NCT01858168, NCT04067115 |
| Nivolumab M.D. Anderson Cancer Center | Relapsed or refractory | Antibody | Ph2 | NCT03449108, NCT03628209, NCT04803877 |
| Palbociclib Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT03155620, NCT03526250 |
| Psilocybin University Health Network, Toronto | Advanced or metastatic | Other or not recognised | Ph2 | NCT07820033, NCT07820033, NCT06416085 |
| Regorafenib Institute of Mother and Child, Warsaw, Poland | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT05395741, NCT04803877, NCT04803877 |
| Sirolimus H. Lee Moffitt Cancer Center and Research Institute | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07725380, NCT02574728, NCT01625351 |
| Vincristine Milton S. Hershey Medical Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06541262, NCT04890093, NCT06709495 |
| Abemaciclib Eli Lilly and Company | Untagged | Small molecule | Ph2 | NCT05440786, NCT04040205 |
| Atezolizumab M.D. Anderson Cancer Center | Relapsed or refractory | Antibody | Ph2 | NCT05019703, NCT06492954 |
| Cabozantinib Ipsen | Maintenance | Small molecule | Ph2 | NCT06341712, NCT05135975 |
| Cabozantinib M.D. Anderson Cancer Center | Relapsed or refractory | Small molecule | Ph2 | NCT05019703, NCT06156410 |
| Cyclophosphamide Valo Therapeutics Oy | Untagged | Small molecule | Ph2 | NCT05492682, NCT07321912 |
| Dinutuximab National Cancer Institute (NCI) | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT04751383, NCT04238819 |
| Dostarlimab GlaxoSmithKline | Untagged | Antibody | Ph1/Ph2 | NCT04544995, NCT06521567 |
| Eflornithine Milton S. Hershey Medical Center | Untagged | Other or not recognised | Ph2 | NCT07321912, NCT06465199 |
| Ensartinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03213652, NCT03155620 |
| Erdafitinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03210714, NCT03155620 |
| GM-CSF Memorial Sloan Kettering Cancer Center | Relapsed or refractory | Other or not recognised | Ph2 | NCT02502786, NCT04238819 |
| Ifosfamide Milton S. Hershey Medical Center | Untagged | Small molecule | Ph2 | NCT07321912, NCT07477457 |
| Ivosidenib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT04195555 |
| Larotrectinib Sulfate National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213704 |
| Melphalan Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Relapsed or refractory | Other or not recognised | Ph2 | NCT01804634, NCT01625351 |
| Methotrexate Milton S. Hershey Medical Center | Untagged | Other or not recognised | Ph2 | NCT07321912, NCT07477457 |
| Olaparib Dana-Farber Cancer Institute | Relapsed or refractory | Small molecule | Ph2 | NCT04417062, NCT03155620 |
| Samotolisib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213678 |
| Selpercatinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04320888, NCT03155620 |
| Sunitinib University of Colorado, Denver | Untagged | Small molecule | Ph2 | NCT03900793, NCT07477457 |
| Tazemetostat National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213665 |
| Tegavivint Emory University | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07144254, NCT04851119 |
| Temozolomide Eli Lilly and Company | Untagged | Small molecule | Ph2 | NCT05440786, NCT01858168 |
| Tipifarnib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04284774, NCT03155620 |
| Ulixertinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03698994, NCT03155620 |
| Zanzalintinib Northwestern University | Advanced or metastatic | Small molecule | Ph2 | NCT06571734, NCT07193550 |
Showing the 60 most advanced of 272 programs.
Assets over time
171 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | M.D. Anderson Cancer Center | |
| Cabozantinib S-malate | National Cancer Institute (NCI) | |
| Doxorubicin | National Cancer Institute (NCI) | |
| Experimental group : Cabometyx ® | Gustave Roussy, Cancer Campus, Grand Paris | |
| HS-20093 | Hansoh BioMedical R&D Company | |
| Cabozantinib | Ipsen | |
| Abemaciclib | Eli Lilly and Company | |
| Zanzalintinib | Northwestern University | |
| Regorafenib | Institute of Mother and Child, Warsaw, Poland | |
| Lurbinectedin | Jazz Pharmaceuticals | |
| Ensartinib | National Cancer Institute (NCI) | |
| Tegavivint | Emory University | |
| Psilocybin | University Health Network, Toronto | |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | |
| Palbociclib | Pfizer | |
| Mifamurtide | Anna Raciborska | |
| Atezolizumab | M.D. Anderson Cancer Center | |
| Eflornithine | Milton S. Hershey Medical Center | |
| Olaparib | Dana-Farber Cancer Institute | |
| Aldesleukin | M.D. Anderson Cancer Center | |
| Hydroxychloroquine | M.D. Anderson Cancer Center | |
| LY2880070 | Memorial Sloan Kettering Cancer Center | |
| High-dose Methotrexate | Wake Forest University Health Sciences | |
| dasatinib | City of Hope Medical Center | |
| Iscador*P | Hackensack Meridian Health | |
| Durvalumab | M.D. Anderson Cancer Center | |
| Multiple sarcoma-specific CAR-T cells and sarcoma vaccines | Shenzhen Geno-Immune Medical Institute | |
| pp65 RNA LP | University of Florida | |
| Sarcoma-specific CAR-T cells | Shenzhen Geno-Immune Medical Institute | |
| Zilovertamab vedotin | Merck Sharp & Dohme LLC |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| FOSTER · NCT07871864 Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse 8 countries, 0% of sites in the US Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | recruiting | 2026-10-13 | 2035-01 |
| NCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Single-country: China (2 sites) Decision brief → | Ph3 | Hansoh BioMedical R&D Company | completed | 2025-04-20 | 2026-06-17 |
| NCT06820957 Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Single-country: United States (8 sites) Decision brief → | Ph2/Ph3 | Children's Oncology Group | terminated | 2025-02-11 | 2026-06-30 |
| NCT05691478 A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma 4 countries, 90% of sites in the US Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | suspended | 2023-01-20 | 2030-03-20 |
| NCT05235165 Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma 6 countries, 94% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2022-02-11 | 2031-03-31 |
| NCT02306161 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma 3 countries, 95% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-12-03 | 2021-03-31 |
| NCT02180867 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery 3 countries, 96% of sites in the US Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | completed | 2014-07-03 | 2019-06-30 |
| BONE DINIRRA · NCT07853105 Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Single-country: France (12 sites) Decision brief → | Ph1/Ph2 | University Hospital, Strasbourg, France | not yet recruiting | 2026-10-01 | 2031-02 |
| NCT07830667 A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-21 | 2033-06-30 |
| PEARL RCT · NCT07820033 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial Single-country: Canada (1 site) Decision brief → | Ph2 | University Health Network, Toronto | not yet recruiting | 2026-09-15 | 2028-12-30 |
| NCT07801222 A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma Single-country: Moldova (1 site) Decision brief → | Ph1/Ph2 | SOTIO Biotech a.s. | not yet recruiting | 2026-09-03 | 2029-01-19 |
| Dragonfly · NCT07787429 Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma Single-country: Poland (1 site) Decision brief → | Ph2 | Anna Raciborska | recruiting | 2026-08-26 | 2033-07-31 |
| NCT07781891 RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | not yet recruiting | 2026-08-24 | 2031-06-30 |
| NCT07725380 Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | H. Lee Moffitt Cancer Center and Research Institute | recruiting | 2026-07-24 | 2031-08 |
| NCT07619950 EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma No sites listed Decision brief → | Ph2 | Yonsei University | not yet recruiting | 2026-06-02 | 2028-11-30 |
| NCT07602049 Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | recruiting | 2026-05-22 | 2026-11-30 |
| NCT07560826 The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma Single-country: United States (9 sites) Decision brief → | Ph2 | Wake Forest University Health Sciences | recruiting | 2026-05-01 | 2028-12 |
| NCT07560410 Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Single-country: Taiwan (1 site) Decision brief → | Ph1/Ph2 | China Medical University Hospital | not yet recruiting | 2026-05-01 | 2029-01-15 |
| NCT07479732 Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Peking University People's Hospital | recruiting | 2026-03-18 | 2027-03-05 |
| NCT07477457 A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-03-17 | 2028-03 |
| NCT07444918 Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors No sites listed Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | not yet recruiting | 2026-03-03 | 2027-12-01 |
| NCT07428993 Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | recruiting | 2026-02-24 | 2034-12 |
| NCT07357519 Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Lantheus Medical Imaging | recruiting | 2026-01-22 | 2027-08 |
| NCT07321912 Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Single-country: United States (3 sites) Decision brief → | Ph2 | Milton S. Hershey Medical Center | recruiting | 2026-01-07 | 2031-06-01 |
| NCT07193550 A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-09-26 | 2029-10-31 |
| NCT07142863 Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients Single-country: China (1 site) Decision brief → | Ph2 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | not yet recruiting | 2025-08-27 | 2026-08-31 |
| NCT07092306 A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma No sites listed Decision brief → | Ph2 | Tang Xiaodong | not yet recruiting | 2025-07-29 | 2027-05-01 |
| BAH2573-103 · NCT07066982 Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2025-07-15 | 2027-12-10 |
| DFMO · NCT06892678 DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Montefiore Medical Center | recruiting | 2025-03-25 | 2030-04 |
| NCT06709495 Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | David S Shulman, MD | recruiting | 2024-11-29 | 2028-11-01 |
| ANTARES · NCT06638931 Agnostic Therapy in Rare Solid Tumors Single-country: Brazil (5 sites) Decision brief → | Ph2 | Instituto do Cancer do Estado de São Paulo | active not recruiting | 2024-10-15 | 2027-07 |
| NCT06625190 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Florida | recruiting | 2024-10-03 | 2030-02 |
| LUPARPED · NCT06607692 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Single-country: Spain (1 site) Decision brief → | Ph1/Ph2 | Fundación de investigación HM | recruiting | 2024-09-23 | 2029-07 |
| NCT06571734 XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Single-country: United States (1 site) Decision brief → | Ph2 | Northwestern University | recruiting | 2024-08-26 | 2028-07-01 |
| IACE-OS · NCT06562673 Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shanghai 6th People's Hospital | completed | 2024-08-20 | 2025-04-17 |
| NCT06541262 Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 2 countries, 96% of sites in the US Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-08-07 | 2030-11-01 |
| NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer 6 countries, 30% of sites in the US Decision brief → | Ph1/Ph2 | GlaxoSmithKline | active not recruiting | 2024-07-26 | 2026-10-13 |
| NCT06465199 Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Single-country: United States (14 sites) Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-06-18 | 2033-05 |
| NCT06416085 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer Single-country: Canada (1 site) Decision brief → | Ph2 | University Health Network, Toronto | active not recruiting | 2024-05-16 | 2026-12-15 |
| NCT06395103 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) 23 countries, 24% of sites in the US Decision brief → | Ph1/Ph2 | Merck Sharp & Dohme LLC | recruiting | 2024-05-01 | 2029-03-31 |
| CabOSTar · NCT06341712 Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma 10 countries, 6% of sites in the US Decision brief → | Ph2 | Ipsen | terminated | 2024-04-02 | 2026-02-27 |
| NCT06239272 NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2024-02-02 | 2034-06 |
| PerVision · NCT06094101 Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Single-country: Germany (4 sites) Decision brief → | Ph1/Ph2 | University Hospital Tuebingen | recruiting | 2023-10-23 | 2027-06 |
| NCT05968768 To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Single-country: Poland (2 sites) Decision brief → | Ph2 | Anna Raciborska | recruiting | 2023-08-01 | 2027-05-01 |
| LiFFT · NCT05918640 Lurbinectedin in FET-Fused Tumors Single-country: United States (6 sites) Decision brief → | Ph1/Ph2 | Children's Hospital of Philadelphia | recruiting | 2023-06-26 | 2028-07-30 |
| NCT05734066 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma 2 countries, 94% of sites in the US Decision brief → | Ph1/Ph2 | Jazz Pharmaceuticals | recruiting | 2023-02-17 | 2028-01-28 |
| NCT05726383 Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma Single-country: United States (2 sites) Decision brief → | Ph2 | Hackensack Meridian Health | recruiting | 2023-02-13 | 2028-12-31 |
| NCT05703854 Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | suspended | 2023-01-30 | 2027-09-30 |
| RNA PRIME · NCT05660408 RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Florida | active not recruiting | 2022-12-21 | 2033-10 |
| NCT05642455 SPEARHEAD-3 Pediatric Study Single-country: United States (10 sites) Decision brief → | Ph1/Ph2 | USWM CT, LLC | recruiting | 2022-12-08 | 2026-10-01 |
| NCT05588648 Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma 2 countries, 14% of sites in the US Decision brief → | Ph1/Ph2 | MedPacto, Inc. | recruiting | 2022-10-20 | 2027-12 |
| NCT05440786 CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma 7 countries, 17% of sites in the US Decision brief → | Ph2 | Eli Lilly and Company | active not recruiting | 2022-07-01 | 2025-01-15 |
| Regbone · NCT05395741 Regorafenib in Patients With Refractory Primary Bone Tumors Single-country: Poland (2 sites) Decision brief → | Ph1/Ph2 | Institute of Mother and Child, Warsaw, Poland | completed | 2022-05-27 | 2025-09-12 |
| NCT05275426 A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | completed | 2022-03-11 | 2025-08-11 |
| NCT05199584 A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Single-country: United States (16 sites) Decision brief → | Ph2 | Endeavor Biomedicines, Inc. | completed | 2022-01-20 | 2024-02-20 |
| PEMBROCABOSARC · NCT05182164 Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Single-country: France (10 sites) Decision brief → | Ph2 | Institut Bergonié | recruiting | 2022-01-10 | 2026-12 |
| NCT05135975 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2021-11-26 | 2026-07 |
| NCT05106777 Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | active not recruiting | 2021-11-04 | 2025-12-10 |
| NCT05071209 Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors 2 countries, 97% of sites in the US Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | active not recruiting | 2021-10-08 | 2024-09-30 |
| NCT05046314 A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma Single-country: China (8 sites) Decision brief → | Ph2 | Shanghai Pharmaceuticals Holding Co., Ltd | completed | 2021-09-16 | 2025-02-05 |
| NCT05019703 Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Single-country: United States (2 sites) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2021-08-25 | 2027-12-31 |
| NCT04901702 Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma 2 countries, 70% of sites in the US Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2021-05-25 | 2026-12-31 |
| NCT04890093 Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | suspended | 2021-05-18 | 2026-12-31 |
| NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Single-country: United States (21 sites) Decision brief → | Ph1/Ph2 | Children's Oncology Group | recruiting | 2021-04-20 | 2028-06-30 |
| NCT04803877 SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Single-country: United States (8 sites) Decision brief → | Ph2 | Sarcoma Alliance for Research through Collaboration | active not recruiting | 2021-03-18 | 2025-11 |
| REGOMAIN · NCT04698785 Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients Single-country: France (16 sites) Decision brief → | Ph2 | Centre Leon Berard | recruiting | 2021-01-07 | 2026-07-21 |
| DOSa · NCT04668300 Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2020-12-16 | 2027-06-30 |
| NCT04616560 Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor Single-country: United States (32 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | recruiting | 2020-11-05 | 2027-12-31 |
| EPOP-SARCOMA · NCT04515459 Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma Single-country: France (1 site) Decision brief → | Ph2 | Institut Claudius Regaud | recruiting | 2020-08-17 | 2029-11 |
| NCT04433221 Combination Immunotherapy Targeting Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2020-06-16 | 2029-05-31 |
| NCT04417062 Olaparib With Ceralasertib in Recurrent Osteosarcoma Single-country: United States (4 sites) Decision brief → | Ph2 | Dana-Farber Cancer Institute | active not recruiting | 2020-06-04 | 2025-06-01 |
| NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial 3 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-03-25 | 2024-09-30 |
| NCT04284774 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial 2 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-02-26 | 2024-03-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) 3 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2019-12-12 | 2025-03-31 |
| U01CA236220 · NCT04067115 SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Single-country: United States (6 sites) Decision brief → | Ph1/Ph2 | Sarcoma Alliance for Research through Collaboration | completed | 2019-08-26 | 2025-04-24 |
| NCT04040205 Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Single-country: United States (4 sites) Decision brief → | Ph2 | Medical College of Wisconsin | recruiting | 2019-07-31 | 2027-06-01 |
| NCT03965234 Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Roswell Park Cancer Institute | recruiting | 2019-05-28 | 2029-05-25 |
| NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors 13 countries, 67% of sites in the US Decision brief → | Ph2 | Pfizer | completed | 2018-10-17 | 2024-08-26 |
| NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2018-10-09 | 2022-03-31 |
| NCT03678883 9-ING-41 in Patients With Advanced Cancers 7 countries, 61% of sites in the US Decision brief → | Ph2 | Actuate Therapeutics Inc. | active not recruiting | 2018-09-20 | 2026-06 |
| SARCOME13 · NCT03643133 Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients Single-country: France (31 sites) Decision brief → | Ph2 | UNICANCER | active not recruiting | 2018-08-22 | 2026-09 |
| NCT03598595 Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2018-07-26 | 2027-05-31 |
| NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-05-16 | 2023-03-31 |
| NCT03449108 LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2018-02-28 | 2027-04-30 |
| NCT03449901 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer Single-country: United States (4 sites) Decision brief → | Ph2 | Washington University School of Medicine | completed | 2018-02-28 | 2022-07-08 |
| NCT03373097 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Single-country: Italy (1 site) Decision brief → | Ph1/Ph2 | Bambino Gesù Hospital and Research Institute | active not recruiting | 2017-12-14 | 2026-12 |
| NCT03356782 Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2017-11-29 | 2029-12-31 |
| NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) 4 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2025-09-30 |
| NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2024-09-30 |
| NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2023-09-30 |
| NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2022-03-31 |
| NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-07 | 2023-09-30 |
| NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) 4 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-05-16 | 2025-03-31 |
| NCT03006848 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Single-country: United States (4 sites) Decision brief → | Ph2 | St. Jude Children's Research Hospital | completed | 2016-12-30 | 2020-03-18 |
| NCT02945800 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Single-country: United States (14 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | completed | 2016-10-26 | 2024-11-19 |
| NCT02880319 Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone Single-country: United States (1 site) Decision brief → | Ph2 | Dana-Farber Cancer Institute | active not recruiting | 2016-08-26 | 2022-05 |
| NCT02867592 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Single-country: United States (142 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2016-08-16 | 2021-06-30 |
| STARTRK-NG · NCT02650401 Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options 9 countries, 58% of sites in the US Decision brief → | Ph1/Ph2 | Hoffmann-La Roche | active not recruiting | 2016-01-08 | 2027-06-30 |
| AflacST1502 · NCT02574728 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Emory University | active not recruiting | 2015-10-14 | 2026-06 |
| NCT02502786 Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma Single-country: United States (3 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2015-07-20 | 2027-07 |
| PEMBROSARC · NCT02406781 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial Single-country: France (8 sites) Decision brief → | Ph2 | Institut Bergonié | completed | 2015-04-02 | 2020-11-24 |
| REGOBONE · NCT02389244 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Single-country: France (19 sites) Decision brief → | Ph2 | UNICANCER | completed | 2015-03-17 | 2024-10-25 |
| NCT02243605 Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma Single-country: France (11 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2014-09-18 | 2019-06-30 |
| NCT01804634 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | recruiting | 2013-03-05 | 2027-01 |
| NCT01590069 Aerosolized Aldesleukin in Treating Patients With Lung Metastases Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2012-05-02 | 2029-04-30 |
| NCT00840047 Methionine PET/CT Studies In Patients With Cancer Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2009-02-10 | 2027-07-27 |
| NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | terminated | 2008-11-10 | 2010-04-30 |
| NCT00407433 Clinical Studies of Gemcitabine-Oxaliplatin Single-country: France (1 site) Decision brief → | Ph2 | Gustave Roussy, Cancer Campus, Grand Paris | completed | 2006-12-05 | – |
| NCT00186992 Radiation Therapy to Treat Musculoskeletal Tumors Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2005-09-16 | 2023-09-15 |
| GD2CART-BEV · NCT07897968 GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Single-country: Germany (1 site) Decision brief → | Ph1 | Universität Münster | not yet recruiting | 2026-10-27 | 2031-09-30 |
| NCT07773454 Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors No sites listed Decision brief → | Ph1 | Exelixis | not yet recruiting | 2026-08-19 | 2028-07-31 |
| NCT07695311 EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT Single-country: United States (1 site) Decision brief → | Ph1 | Rabi Hanna | not yet recruiting | 2026-07-10 | 2029-10 |
| NCT07648069 Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma Single-country: China (1 site) Decision brief → | Ph1 | Sun Yat-sen University | recruiting | 2026-06-15 | 2026-12-31 |
| NCT07596693 KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma) Single-country: China (1 site) Decision brief → | Ph1 | TCRx Therapeutics Co.Ltd | recruiting | 2026-05-19 | 2027-12-31 |
| NCT07297979 Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) 2 countries, 77% of sites in the US Decision brief → | Ph1 | Amgen | recruiting | 2025-12-22 | 2030-05-26 |
| NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial Single-country: United States (1 site) Decision brief → | Ph1 | Fred Hutchinson Cancer Center | recruiting | 2025-11-12 | 2029-01-31 |
| NCT07222735 Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2025-10-30 | 2030-11-05 |
| NCT07211737 NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2025-10-08 | 2029-04 |
| NCT07197554 A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies Single-country: United States (6 sites) Decision brief → | Ph1 | SEED Therapeutics, Inc. | recruiting | 2025-09-29 | 2029-12-31 |
| METTSEO · NCT07194044 Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Single-country: United States (21 sites) Decision brief → | Ph1 | H. Lee Moffitt Cancer Center and Research Institute | recruiting | 2025-09-26 | 2030-10 |
| SABRE · NCT07172958 Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Single-country: United States (2 sites) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2025-09-15 | 2041-12 |
| NCT07144254 Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Single-country: United States (2 sites) Decision brief → | Ph1 | Emory University | recruiting | 2025-08-27 | 2028-05 |
| NCT07052383 Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas Single-country: China (1 site) Decision brief → | Ph1 | Tcelltech Inc. | suspended | 2025-07-04 | 2027-10-10 |
| NCT06926283 A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors Single-country: China (4 sites) Decision brief → | Ph1 | Hangzhou DAC Biotechnology Co., Ltd. | recruiting | 2025-04-13 | 2030-04 |
| NCT06577987 Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Single-country: United States (10 sites) Decision brief → | Ph1 | Circle Pharma | active not recruiting | 2024-08-29 | 2027-01-14 |
| NCT06566092 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants Single-country: United States (5 sites) Decision brief → | Ph1 | Iovance Biotherapeutics, Inc. | terminated | 2024-08-22 | 2026-06-19 |
| NCT06531486 A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | recruiting | 2024-08-01 | 2029-05-15 |
| NCT06500819 Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Stanford University | recruiting | 2024-07-15 | 2029-07 |
| AflacST2301 · NCT06492954 Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Emory University | recruiting | 2024-07-09 | 2027-06 |
| NCT06474676 T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. Single-country: United States (1 site) Decision brief → | Ph1 | M.D. Anderson Cancer Center | recruiting | 2024-06-26 | 2030-12-31 |
| NCT06438783 TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors Single-country: China (5 sites) Decision brief → | Ph1 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | terminated | 2024-06-03 | 2025-06-18 |
| Cytalux · NCT06235125 Safety and Feasibility of Intraoperative Visualization With Cytalux in Children Single-country: United States (1 site) Decision brief → | Ph1 | Ann & Robert H Lurie Children's Hospital of Chicago | recruiting | 2024-01-31 | 2026-08-31 |
| NCT06156410 Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas Single-country: United States (4 sites) Decision brief → | Ph1 | Children's Hospital of Philadelphia | recruiting | 2023-12-05 | 2027-11 |
| NCT06008483 A Dose Finding Study to Treat Bone Tumor(s) Single-country: United States (4 sites) Decision brief → | Ph1 | QSAM Therapeutics, Inc. | terminated | 2023-08-23 | 2024-08-08 |
| REGO-INTER-EWI · NCT05830084 Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma 6 countries, 0% of sites in the US Decision brief → | Ph1 | Gustave Roussy, Cancer Campus, Grand Paris | active not recruiting | 2023-04-26 | 2027-04 |
| NCT05621668 A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | M.D. Anderson Cancer Center | active not recruiting | 2022-11-18 | 2027-09-30 |
| NCT05605522 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours 2 countries, 88% of sites in the US Decision brief → | Ph1 | 3B Pharmaceuticals GmbH | terminated | 2022-11-04 | 2024-07-19 |
| NCT05492682 START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer 2 countries, 0% of sites in the US Decision brief → | Ph1 | Valo Therapeutics Oy | recruiting | 2022-08-08 | 2027-04-30 |
| Aflac-NBL-2002 · NCT05400603 Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Emory University | recruiting | 2022-06-01 | 2026-12 |
| NCT05312411 A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2022-04-05 | 2025-03-12 |
| NCT05227326 AOH1996 for the Treatment of Refractory Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph1 | City of Hope Medical Center | recruiting | 2022-02-07 | 2029-09-13 |
| NCT05210374 Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | Case Comprehensive Cancer Center | recruiting | 2022-01-27 | 2026-09-01 |
| NCT04995003 HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2021-08-06 | 2028-06-30 |
| NCT04897321 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2021-05-21 | 2027-03-01 |
| NCT04833582 A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma 2 countries, 71% of sites in the US Decision brief → | Ph1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | completed | 2021-04-06 | 2023-08-30 |
| NCT04751383 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma 2 countries, 82% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | terminated | 2021-02-12 | 2024-09-30 |
| NCT04616248 In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Single-country: United States (2 sites) Decision brief → | Ph1 | University of Southern California | active not recruiting | 2020-11-04 | 2027-01-09 |
| NCT04544995 Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) Single-country: United Kingdom (2 sites) Decision brief → | Ph1 | GlaxoSmithKline | terminated | 2020-09-10 | 2025-04-23 |
| NCT04539366 Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Single-country: United States (6 sites) Decision brief → | Ph1 | National Cancer Institute (NCI) | suspended | 2020-09-07 | 2040-12-31 |